Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16659195 | 0.80 | MAOA (0.36) | MAOB | |
| SCHEMBL16659200 | 0.68 | MAOB (0.33) | MAOBGABRA1GABRB2 | |
| SCHEMBL9904847 | 0.67 | BCL2L1 (0.33) | MAOB | |
| SCHEMBL548661 | 0.64 | MEN1 (0.45) | — | |
| SCHEMBL17019758 | 0.62 | — | — | |
| SCHEMBL16659191 | 0.61 | MAOA (0.36) | MAOB | |
| SCHEMBL11267610 | 0.60 | MAOB (0.42) | MAOBGABRA1GABRB2 | |
| SCHEMBL9904807 | 0.59 | MAOA (0.33) | MAOB | |
| SCHEMBL10235104 | 0.59 | GABRA1 (0.40) | MAOBGABRA1GABRB2 | |
| SCHEMBL20612836 | 0.58 | MAOB (0.38) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | MAOB 2416/4885GABRA1 218/4885GABRB2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.